6月4日周三，港股市场生物医药板块再度走强，其中中国抗体-B（03681）表现尤为亮眼，盘中大涨18.5%，引发市场广泛关注。
根据最新行情数据，中国抗体-B并非孤军奋战。同属生物医药板块的信达生物（01801）涨近13%，北海康成-B（01228）涨幅超过10%。这一轮涨势凸显了投资者对生物医药行业的持续看好。
分析人士指出，生物医药股的集体走强可能与行业政策、研发进展或市场需求等多方面因素有关。作为板块龙头，中国抗体-B的强劲表现不仅反映了公司自身的发展前景，也为整个行业注入了信心。投资者应密切关注后续可能发布的相关利好消息，同时也要警惕短期快速上涨后可能出现的回调风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.